# Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemia

## Authors

Kathelijn Verdeyen,[1,2*] Tom Reuvekamp,[1-3*] Walter J.F.M. van der Velden,[4] Bas J. Wouters,[5] Peter A. von dem Borne,[6] Anna van Rhenen,[7] Birgit I. Lissenberg-Witte,[8] Daniëlle van Lammeren,[9] Geerte L. van Sluis,[10] Eva de Jongh,[11] Roel B. Fiets,[12] Maarten F. Corsten,[13] Arie C. van der Spek,[14] Anke M. Gerrits,[15] Esther R. van Bladel,[16] Lidwine W. Tick,[17] Okke de Weerdt,[18] Bregje van Zaane,[19] Marjan J. Cruijsen,[20] Eduardus F.M. Posthuma,[21] Catharina H.M.J. van Elssen,[22,23] Saskia K. Klein,[24] Arjan A. van de Loosdrecht[2,3] and David C. de Leeuw[2,3]

[1]Amsterdam UMC location Universiteit van Amsterdam, Department of Hematology, Amsterdam; [2]Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam; [3]Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam; [4]Radboud University Medical Center, Department of Hematology, Nijmegen; [5]Erasmus Medical Center, Department of Hematology, Rotterdam; [6]Leiden University Medical Center, Department of Hematology, Leiden; [7]University Medical Center Utrecht, Department of Hematology, Utrecht; [8]Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam; [9]HagaZiekenhuis, Department of Hematology, The Hague; [10]Isala Clinics, Department of Internal Medicine, Zwolle; [11]Albert Schweitzer Hospital, Department of Internal Medicine, Dordrecht; [12]Amphia Hospital, Department of Internal Medicine, Breda; [13]Meander Medical Center, Department of Hematology, Amersfoort; [14]Northwest Clinics, Department of Internal Medicine, Alkmaar; [15]OLVG, Department of Internal Medicine, Amsterdam; [16]Slingeland Hospital, Department of Internal Medicine, Doetinchem; [17]Máxima Medical Center, Department of Internal Medicine, Veldhoven; [18]Sint Antonius Hospital, Department of Hematology, Nieuwegein; [19]Flevo Hospital, Department of Internal Medicine, Almere; [20]Catharina Hospital, Department of Internal Medicine, Eindhoven; [21]Reinier de Graaf Group, Department of Internal Medicine, Delft; [22]Maastricht University Medical Center+, Department of Internal medicine, Maastricht; [23]Research Institute for Oncology and Reproduction (GROW), Maastricht University, Maastricht and [24]University Medical Center Groningen, Department of Hematology, Groningen, the Netherlands

**KV and TR contributed equally as first authors.*

Correspondence:
D.C. DLEEUW - d.deleeuw@amsterdamumc.nl

https://doi.org/10.3324/haematol.2025.288178

Received: May 8, 2025.
Accepted: September 8, 2025.
Early view: September 18, 2025.

**Supplementary information to Venetoclax-HMA as a bridge to transplant or DLI in relapsed or refractory acute myeloid leukemia**

**Verdeyen and Reuvekamp et al.**

**Supplemental Figures**




**Figure S1.** Overall survival and cumulative incidence of relapse in the whole cohort.




**Figure S2. Survival of relapsed and refractory patients from start of venetoclax-HMA.** A) overall survival. B) relapse-free survival. C) cumulative incidence of relapse

## Supplemental Tables

**Table S1.** Mutations stratified by refractory and relapsed patients.

| Characteristic | **Refractory**, N = 44[1] | **Relapse**, N = 102[1] | p-value[2] |
|---|---|---|---|
| **Age** | 63 (51-70) | 64 (52-69) | >0.9 |
| **Sex: male** | 27 (61%) | 53 (52%) | 0.3 |
| **NPM1** | | | 0.10 |
| Negative | 38 (93%) | 80 (82%) | |
| Positive | 3 (7.3%) | 18 (18%) | |
| **DNMT3A** | | | 0.8 |
| Negative | 11 (73%) | 28 (65%) | |
| Positive | 4 (27%) | 15 (35%) | |
| **TET2** | | | 0.7 |
| Negative | 13 (81%) | 37 (86%) | |
| Positive | 3 (19%) | 6 (14%) | |
| **FLT3-TID** | | | 0.2 |
| Negative | 37 (90%) | 79 (81%) | |
| Positive | 4 (9.8%) | 19 (19%) | |
| **TP53** | | | 0.5 |
| Negative | 32 (82%) | 76 (86%) | |
| Positive | 7 (18%) | 12 (14%) | |
| **IDH1** | | | 0.8 |
| Negative | 36 (92%) | 80 (89%) | |
| Positive | 3 (7.7%) | 10 (11%) | |
| **IDH2** | | | 0.088 |
| Negative | 32 (80%) | 82 (91%) | |
| Positive | 8 (20%) | 8 (8.9%) | |
| **RUNX1** | | | 0.11 |
| Negative | 30 (73%) | 74 (85%) | |
| Positive | 11 (27%) | 13 (15%) | |
| **ASXL1** | | | 0.11 |
| Negative | 29 (74%) | 80 (86%) | |
| Positive | 10 (26%) | 13 (14%) | |
| **Monosomy 17** | | | 0.4 |
| Negative | 37 (86%) | 92 (92%) | |
| Positive | 6 (14%) | 8 (8.0%) | |
| **Inversion 3** | | | >0.9 |
| Negative | 41 (98%) | 97 (97%) | |
| Positive | 1 (2.4%) | 3 (3.0%) | |
| **KRAS/NRAS** | | | 0.6 |
| Negative | 16 (100%) | 40 (91%) | |
| Positive | 0 (0%) | 4 (9.1%) | |

| Characteristic | **Refractory**, N = 44[1] | **Relapse**, N = 102[1] | **p-value**[2] |
|---|---|---|---|
| **CEBPA** | | | 0.7 |
| Negative | 39 (98%) | 92 (94%) | |
| Positive | 1 (2.5%) | 6 (6.1%) | |

[1]Median (IQR); n (%)

[2]Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test